The takeover also means that a related $11 billion transaction in which Novo Holdings' subsidiary Novo Nordisk takes control of three of Catalent’s fill-and-finish facilities in Italy ...

Novo Nordisk also purchased three of Catalent's fill-finish facilities from Novo Holdings. They are located in Bloomington in the US state of Indiana, Brussels, Belgium and Anagni, Italy along ...

Catalent will continue to operate independently and separately from Novo Holdings and Novo Nordisk. The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will ...

with facilities in Belgium, Spain, the Netherlands, and Sweden, today announced that it has successfully completed the acquisition of Catalent’s state-of-the-art drug product manufacturing ...

with facilities in Belgium, Spain, the Netherlands, and Sweden, today announced that it has successfully completed the acquisition of Catalent’s state-of-the-art drug product manufacturing facility in ...